| July 1, 2027 |
ONC |
A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy Participants |
Trial Milestone |
Phase 1 |
| July 6, 2027 |
REGN |
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer |
Trial Milestone |
Phase 1/Phase 2 |
| July 6, 2027 |
NVO |
A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney Function |
Trial Milestone |
Phase 1 |
| July 7, 2027 |
KLRA |
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity |
Trial Milestone |
Phase 2 |
| July 14, 2027 |
MRK |
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
ABBV |
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
ABBV |
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan |
Trial Milestone |
Phase 1 |
| July 15, 2027 |
ABBV |
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
ARGX |
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
NBIX |
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
NBIX |
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
NBIX |
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
ARWR |
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia |
Trial Milestone |
Phase 1/Phase 2 |
| July 15, 2027 |
ALKS |
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201) |
Trial Milestone |
Phase 2 |
| July 15, 2027 |
NTLA |
A Phase 3 Study of NTLA-2001 in ATTRv-PN |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
VTRS |
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
TVTX |
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study) |
Trial Milestone |
Phase 1/Phase 2 |
| July 15, 2027 |
KRYS |
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors |
Trial Milestone |
Phase 1/Phase 2 |
| July 15, 2027 |
MESO |
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
TLSA |
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab |
Trial Milestone |
Phase 2 |
| July 15, 2027 |
COAG |
A Study Assessing HMB-002 in Participants With Von Willebrand Disease |
Trial Milestone |
Phase 1/Phase 2 |
| July 15, 2027 |
NGEN |
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
CRIS |
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) |
Trial Milestone |
Phase 1/Phase 2 |
| July 20, 2027 |
MRNA |
A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults |
Trial Milestone |
Phase 1 |
| July 27, 2027 |
INCY |
Study of INCB123667 in Subjects With Advanced Solid Tumors |
Trial Milestone |
Phase 1 |
| July 30, 2027 |
AZN |
Volrustomig Priming Regimens Exploratory Phase II Platform Study |
Trial Milestone |
Phase 2 |
| July 30, 2027 |
JNJ |
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment |
Trial Milestone |
Phase 3 |
| July 30, 2027 |
INCY |
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva |
Trial Milestone |
Phase 2 |
| July 30, 2027 |
ONC |
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer |
Trial Milestone |
Phase 1 |
| July 30, 2027 |
IDYA |
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types |
Trial Milestone |
Phase 1 |
| July 30, 2027 |
ONCY |
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab |
Trial Milestone |
Phase 1/Phase 2 |
| July 30, 2027 |
RIGL |
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors |
Trial Milestone |
Phase 4 |
| July 31, 2027 |
AMGN |
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration |
Trial Milestone |
Phase 3 |
| July 31, 2027 |
ONC |
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment |
Trial Milestone |
Phase 1 |
| July 31, 2027 |
ALNY |
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers |
Trial Milestone |
Phase 1 |
| July 31, 2027 |
TGTX |
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) |
Trial Milestone |
Phase 2 |
| July 31, 2027 |
ANNX |
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) |
Trial Milestone |
Phase 3 |
| July 31, 2027 |
MAIA |
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC |
Trial Milestone |
Phase 3 |